Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pulse Biosciences, Inc. (PLSE), Wednesday announced positive results from the 60-day post-procedure evaluations of four initial patients with atrial fibrillation in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study.
Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report)’s stock price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $9.73 and traded as low as $8.37. Pulse Biosciences shares last traded at $8.60, with a volume of 91,879 shares trading hands. Analyst Upgrades and Downgrades […]
Pulse Biosciences (NASDAQ:PLSE) Trading Down 4 3% theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.